Journal of managed care & specialty pharmacy最新文献

{"title":"Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey.","authors":"James T Kenney, Patrick P Gleason","doi":"10.18553/jmcp.2025.31.2-a.s20","DOIUrl":"10.18553/jmcp.2025.31.2-a.s20","url":null,"abstract":"","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"31 2-a Suppl","pages":"S20-S24"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging trends in patient experience data: Perspectives on the 2024 AMCP Foundation Survey.","authors":"Eleanor M Perfetto","doi":"10.18553/jmcp.2025.31.2-a.s34","DOIUrl":"10.18553/jmcp.2025.31.2-a.s34","url":null,"abstract":"","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"31 2-a Suppl","pages":"S34-S37"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacoequity measurement framework: A tool to reduce health disparities.","authors":"Pranav M Patel, Utibe R Essien, Laura Happe","doi":"10.18553/jmcp.2025.31.2.214","DOIUrl":"10.18553/jmcp.2025.31.2.214","url":null,"abstract":"<p><p><i>Pharmacoequity</i> is a health system and policy goal of ensuring equitable access to high-quality medications for all individuals, regardless of factors such as race, ethnicity, socioeconomic status, or resource availability to reduce health disparities. Although measurement frameworks have been widely used in health equity contexts, a focused framework for pharmacoequity remains a critical gap. In this article, we introduce a novel pharmacoequity measurement framework anchored in the patient medication-use journey. The framework includes the following domains: (1) access to health care services, (2) prescription generation, (3) primary medication nonadherence, (4) secondary medication nonadherence, and (5) medication monitoring. For each domain, we provide examples of outcome measures and potential data sources that can be used for evaluation. We also outline an implementation workflow of the pharmacoequity measurement framework that population health stakeholders can use across various settings (eg, health systems, health plans). The framework provides a structured approach to identify existing gaps in the path toward achieving pharmacoequity and lay the foundation for targeted interventions. Additionally, it enables ongoing monitoring of progress toward achieving pharmacoequity while identifying interventions that are effective, scalable, and sustainable.</p>","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"31 2","pages":"214-224"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging trends in information technology: Perspectives on the 2024 AMCP Foundation Survey.","authors":"George Van Antwerp, Laura Topor","doi":"10.18553/jmcp.2025.31.2-a.s11","DOIUrl":"10.18553/jmcp.2025.31.2-a.s11","url":null,"abstract":"","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"31 2-a Suppl","pages":"S11-S14"},"PeriodicalIF":2.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11785361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States.","authors":"Vakaramoko Diaby, Shubhram Pandey, Vassiki Sanogo, Reem Dhayan Almutairi, Yagyesh Kanoria, Soma S Nag","doi":"10.18553/jmcp.2025.31.1.60","DOIUrl":"10.18553/jmcp.2025.31.1.60","url":null,"abstract":"<p><strong>Background: </strong>Bipolar disorder is a severe recurrent, episodic psychiatric condition with a worldwide prevalence of approximately 1%, affecting more than 5 million adults in the United States in 2020. A subtype, bipolar I disorder (BP-I), which accounts for approximately one-quarter of cases, is associated with impairments in psychosocial functioning and quality of life. Recommended treatment options include daily oral, or long-acting injectable, antipsychotics, including the aripiprazole once every month formulation, which has been shown to improve adherence compared with oral treatments. A new formulation of aripiprazole for administration once every 2 months ready to use (Ari 2MRTU) has been shown to have similar efficacy to monthly treatment, with only 6 doses annually.</p><p><strong>Objective: </strong>To estimate the financial impact of introducing the new formulation of aripiprazole as a treatment option for adults diagnosed with BP-I in the United States.</p><p><strong>Methods: </strong>A cohort of eligible patients with BP-I was selected from a hypothetical US health plan of 1 million members, and the treatment costs modeled with a 3-year time horizon, in scenarios with or without the addition of Ari 2MRTU. Inputs into the model included user-definable estimates of the current and projected market share of the available antipsychotics, forecast uptake of aripiprazole new formulation, acquisition, initiation, and administration costs, hospitalization costs, time on treatment, and patient adherence. The budget impact was estimated as the difference in the annual cost for the total cohort for the current and new scenarios, the cost per member per month, and the cost per treated member per month. Deterministic sensitivity analyses were also conducted to examine the extent to which the model results were affected by variations in individual input parameters.</p><p><strong>Results: </strong>The total budget impact of introducing a formulation of Ari 2MRTU as maintenance monotherapy for treating a cohort of eligible patients with BP-I in the United States from a health plan of 1 million members was estimated to be $898,930 over 3 years, representing a per member per month cost saving of $0.025 and a per treated member per month cost saving of $2.43. The sensitivity analysis supports a modest reduction in budget, with the main driver being adherence with medication regimen.</p><p><strong>Conclusions: </strong>The introduction of Ari 2MRTU as a maintenance treatment for adults with BP-I is expected to have a neutral effect on payer budgets in the United States and is a potentially favorable option for patients who prefer less frequent dosing.</p>","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"31 1","pages":"60-67"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey.","authors":"James T Kenney, Patrick P Gleason","doi":"10.18553/jmcp.2025.31.1-b.s20","DOIUrl":"10.18553/jmcp.2025.31.1-b.s20","url":null,"abstract":"","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"31 1-b Suppl","pages":"S20-S24"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist-supported electronic outreach to address medication nonadherence for Medicare Advantage enrollees.","authors":"Natasha Virrueta, Valerie Valdiviez, Trevor Beutel, Oliver Titus, Sydney Peauroi, Sarah J Billups","doi":"10.18553/jmcp.2025.31.1.33","DOIUrl":"10.18553/jmcp.2025.31.1.33","url":null,"abstract":"<p><strong>Background: </strong>Improved medication adherence, represented as an increase in the proportion of days covered (PDC), to chronic medications is associated with better patient outcomes, yet effective strategies to improve adherence are often resource intensive. <b>OBJECTIVE:</b> To quantify the impact of a pharmacist-supported electronic outreach initiative on medication adherence measures and to qualitatively evaluate patient engagement with and response to electronic messaging.</p><p><strong>Methods: </strong>This retrospective cohort evaluation used mixed methods to assess the impact of a population health quality improvement program to address medication adherence for Medicare Advantage enrollees. The intervention was performed between January 1, 2023, and December 31, 2023, by population health teams supporting the University of Colorado Primary Care practices. The teams reviewed insurer-provided lists to identify patients late to refill a medication and sent an electronic health message, a mailed letter, or a phone call conveying concern for adherence. Patient responses requiring clinical intervention or education were triaged to clinical pharmacists for management per their clinical discretion. The proportion of Medicare Advantage enrollees classified as adherent, defined as PDC value of 0.8 or higher, was compared before (2022) and after implementation of the population-based outreach intervention for the 2023 plan year. Qualitative methods were used to evaluate patient response to electronic messages. The text of all patient replies to electronic messages was thematically analyzed and categorized.</p><p><strong>Results: </strong>The proportion of patients classified as adherent to diabetes medications was higher in the postintervention group (87.5%) compared with the preintervention group (83.4%, <i>P</i> = 0.021), whereas the adherence rates in the post- vs prehypertension (89.3% vs 88.7%, <i>P</i> = 0.517) and cholesterol (89.4% vs 89.2%, <i>P</i> = 0.721) groups were not significantly different. The population health teams sent 1,593 electronic health record messages, 1,185 (74.4%) of which were opened, and patients responded to 516 (32.4%). The most common patient response was patients self-reporting being adherent (306, 59.3%); fewer patients admitted to some degree of nonadherence (111, 21.5%). An equal number of patients reported appreciation for (111, 21.5%) and confusion about or irritation with the outreach (111, 21.5%).</p><p><strong>Conclusions: </strong>The University of Colorado Medicine's population health initiative provided mixed results on medication adherence metrics. Electronic health record messaging provided insight into ways to improve the intervention to better engage and assist patients.</p>","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"31 1","pages":"33-41"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Budget impact analysis of including biosimilar adalimumab on formulary: A US payer perspective.","authors":"Sarah McGill","doi":"10.18553/jmcp.2025.31.1.112","DOIUrl":"10.18553/jmcp.2025.31.1.112","url":null,"abstract":"","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"31 1","pages":"112-113"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States.","authors":"Vakaramoko Diaby, Shubhram Pandey, Vassiki Sanogo, Reem Dhayan Almutairi, Yagyesh Kanoria, Soma S Nag","doi":"10.18553/jmcp.2025.31.1.53","DOIUrl":"10.18553/jmcp.2025.31.1.53","url":null,"abstract":"<p><strong>Background: </strong>Schizophrenia is a chronic psychiatric disorder, affecting 1.1% of the adult population in 2020 in the United States. Antipsychotic treatment is commonly used in schizophrenia management to help reduce the likelihood of symptom recurrence and relapse. Aripiprazole once every month, a long-acting injectable antipsychotic formulation with an established efficacy and safety profile, is approved by the United States Food and Drug Administration as a maintenance treatment for schizophrenia. A new ready-to-use formulation of aripiprazole for administration once every 2 months (Ari 2MRTU) has been shown to have similar efficacy to aripiprazole once every month and was designed to improve medication adherence in order to provide antipsychotic treatment and prevent relapses.</p><p><strong>Objective: </strong>To estimate the financial impact of introducing Ari 2MRTU as a treatment option for adult patients diagnosed with schizophrenia in the United States.</p><p><strong>Methods: </strong>A cohort of adult patients with schizophrenia was selected from a hypothetical health plan of 1 million members. Treatment costs were modeled with a 3-year time horizon from 2024 to 2026, in scenarios with or without the addition of Ari 2MRTU. Inputs into the model included estimated current and projected market share of the available antipsychotics, expected uptake of Ari 2MRTU, as well as the acquisition, initiation, and administration costs, hospitalization costs, time on treatment, and patient member medication adherence. The budget impact was estimated as the difference in the annual cost for the total cohort for the current and new scenarios, the cost per member per month and per treated member per month. Deterministic sensitivity analyses were conducted to examine the extent to which the model results were affected by a change in individual all-input parameters.</p><p><strong>Results: </strong>The total budget impact of Ari 2MRTU being adopted as an alternative maintenance monotherapy for treating eligible patients with schizophrenia from a hypothetical US health plan of 1 million members was estimated to be a saving of $26,998 over 3 years. This represented a per member per month saving of $0.001 and a per treated member per month saving of $0.11, whereas a sensitivity analysis indicated that these savings were sensitive to treatment adherence and the acquisition cost of the new formulation.</p><p><strong>Conclusions: </strong>The introduction of Ari 2MRTU as a maintenance treatment for adults with schizophrenia is expected to be cost neutral (with a modest saving) with respect to payer budgets in the United States. This merits consideration as is a potentially favorable option for patients who benefit from less frequent dosing.</p>","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"31 1","pages":"53-59"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142921841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging trends in public policy: Perspectives on the 2024 AMCP Foundation Survey.","authors":"George Van Antwerp, Laura Topor","doi":"10.18553/jmcp.2025.31.1-b.s11","DOIUrl":"10.18553/jmcp.2025.31.1-b.s11","url":null,"abstract":"","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"31 1-b Suppl","pages":"S11-S14"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11780271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143052672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}